Journal of the Neurological Sciences
Volume 206, Issue 1 , Pages 79-83 , 15 January 2003

Isatin, an endogenous MAO inhibitor, improves bradykinesia and dopamine levels in a rat model of Parkinson's disease induced by Japanese encephalitis virus

  • Akihiko Ogata

      Affiliations

    • Corresponding Author InformationCorresponding author. Tel.: +81-11-716-1161x6028; fax: +81-11-700-5356.
    • Department of Neurology, Hokkaido University School of Medicine, Kita-14, Nishi-5, Kita-ku, Sapporo 060-8648, Japan
    • ,
  • Naoya Hamaue

      Affiliations

    • Department of Pharmacology, Faculty of Pharmaceutical Sciences, Health Science University of Hokkaido, Ishikari-Tobetsu, Japan
    • ,
  • Mutsuko Terado

      Affiliations

    • Department of Pharmacology, Faculty of Pharmaceutical Sciences, Health Science University of Hokkaido, Ishikari-Tobetsu, Japan
    • ,
  • Masaru Minami

      Affiliations

    • Department of Pharmacology, Faculty of Pharmaceutical Sciences, Health Science University of Hokkaido, Ishikari-Tobetsu, Japan
    • ,
  • Kazuo Nagashima

      Affiliations

    • Department of Pathology, Hokkaido University School of Medicine, Sapporo, Japan
    • ,
  • Kunio Tashiro

      Affiliations

    • Department of Neurology, Hokkaido University School of Medicine, Kita-14, Nishi-5, Kita-ku, Sapporo 060-8648, Japan

Received 29 January 2002 ,Revised 17 July 2002 ,Accepted 28 August 2002.

References 

  1. Johnson RT, Burke DS, Elwell M, et al.  Japanese encephalitis: immunocytochemical studies of viral antigen and inflammatory cells in fetal cases. Ann. Neurol. 1985;18:567–573
  2. Dickerson RB, Newton JR, Hansen JE. Diagnosis and immediate prognosis of Japanese B encephalitis. Am. J. Med. 1952;12:277–288
  3. Ogata A, Nagashima K, Hall WW, et al.  Japanese encephalitis virus neurotropism is dependent on the degree of neuronal maturity. J. Virol. 1991;65:880–886
  4. Ogata A, Tashiro K, Nukuzuma S, et al.  A rat model of Parkinson's disease induced by Japanese encephalitis virus. J. Neurovirol. 1997;3:141–147
  5. Ogata A, Nagashima K, Yasui K, et al.  Sustained release dosage of thyrotropin-releasing hormone improves experimental Japanese encephalitis virus-induced parkinsonism in rats. J. Neurol. Sci. 1998;159:135–139
  6. Glover V, Battacharya SK, Sandler M. Isatin—a new biological factor. Indian J. Exp. Biol. 1991;29:1–5
  7. Tozawa Y, Ueki A, Manabe S, et al.  Stress-induced increase in urinary isatin excretion in rats—reversal by both dexamethasone and α-methyl-p-tyrosine. Biochem. Pharmacol. 1998;56:1041–1046
  8. Hamaue N, Yamazaki N, Minami M, et al.  Effects of isatin, an endogenous MAO inhibitor, on acetylcholine and dopamine levels in the rat striatum. Biog. Amines. 1999;15:367–377
  9. Hamaue N, Yamazaki N, Terado M, et al.  Urinary isatin concentrations in patients with Parkinson's disease determined by a newly developed HPLC–ECD method. Res. Commun. Mol. Pathol. Pharmacol. 2000;108:63–73
  10. Ogawa N, Hirose Y, Ohara S, et al.  A simple quantitative bradykinesia test in MPTP-treated mice. Res. Commun. Chem. Pathol. Pharmacol. 1985;50:435–441
  11. Glowinski J, Iversen LL. Regional studies of catecholamines in the rat brain: I. The disposition of [3H] norepinephrine, [3H] dopa in the various regions of the brain. J. Neurochem. 1966;13:655–669
  12. Endo T, Minami M, Saito H, et al.  Significance of sulfate conjugated dopamine, epinephrine and norepinephrine in patients with congestive heart failure and chronic hemodialysis; in vitro correlations. Biog. Amines. 1989;6:571–581
  13. Lowry OH, Rosebrough NJ, Farr AL, Randall RJ. Protein measurement with the Folin phenol reagent. J. Biol. Chem. 1951;193:265–275
  14. Wallenstein S, Zucker CL, Fleiss JL. Some statistical methods useful in circulation research. Circ. Res. 1980;47:1–9
  15. Kupsch A, Sautter J, Goetz ME, et al.  Monoamine oxidase-inhibition and MPTP-induced neurotoxicity in the non-human primate: comparison of rasagiline (TVP 1012) with selegiline. J. Neural Transm. 2001;108:985–1009
  16. Pradhan S, Pandey N, Shashank S, et al.  Parkinsonism due to predominant involvement of substantia nigra in Japanese encephalitis. Neurology. 1999;53:1781–1786
  17. Calne DB, Langston JW. Aetiology of Parkinson's disease. Lancet. 1983;ii:1457–1459
  18. Duvoisin RC, Yahr MD. Encephalitis and parkinsonism. Arch. Neurol. 1965;12:227–239
  19. Walters JH. Post-encephalitic parkinson syndrome after meningoencephalitis due to coxsackie virus group B, type 2. N. Engl. J. Med. 1960;263:744–747
  20. Fishman PS, Gass JS, Swoveland PT, et al.  Infection of the basal ganglia by a murine corona virus. Science. 1985;229:877–879
  21. Takahashi M, Yamada T, Nakajima S, et al.  The substantia nigra is a major target for neurovirulent influenza A virus. J. Exp. Med. 1995;181:2161–2169
  22. Dluzen DE. Effects of testosterone upon MPTP-induced neurotoxicity of the nigrostriatal dopaminergic system of C57/B1 mice. Brain Res. 1996;715:113–118
  23. Hamaue N, Minami M, Kanamaru Y, et al.  Identification of isatin, an endogenous MAO inhibitor, in the brain of stoke-prone SHR. Biog. Amines. 1994;10:99–110
  24. Glover V, Halket JM, Watkins PJ, et al.  Isatin: identity with the purified endogenous monoamine oxidase inhibitor tribulin. J. Neurochem. 1988;51:656–659
  25. Kumar P, Bansal RC, Mahmood A. Isatin, an inhibitor of acetylcholinesterase activity in rat brain. Biog. Amines. 1993;9:281–289

PII: S0022-510X(02)00342-8

Journal of the Neurological Sciences
Volume 206, Issue 1 , Pages 79-83 , 15 January 2003

Article Tools

* Image Usage & Resolution